MyBlueDots

ANDOVER, Mass. & HAIFA, Israel–(BUSINESS WIRE)– #AMR–These new members bring decades of experience in medicine, industry, and healthcare policy, strengthening MeMed’s work in host-response technologies.

ANDOVER, Mass. & HAIFA, Israel–(BUSINESS WIRE)– #AMR–These new members bring decades of experience in medicine, industry, and healthcare policy, strengthening MeMed’s work in host-response technologies.

CHAPEL HILL, N.C.–(BUSINESS WIRE)–Areteia Therapeutics, Inc. (“Areteia”), a clinical-stage biotechnology company developing novel inflammation and immunology therapies, with an initial focus on severe eosinophilic asthma, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday January 14, 2025 at 1:30 p.m. PT in San Francisco, CA. A copy of the presentation will be posted on the Company’s website following the presentation. Event:   J.P. M

CHAPEL HILL, N.C.–(BUSINESS WIRE)–Areteia Therapeutics, Inc. (“Areteia”), a clinical-stage biotechnology company developing novel inflammation and immunology therapies, with an initial focus on severe eosinophilic asthma, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday January 14, 2025 at 1:30 p.m. PT in San Francisco, CA. A copy of the presentation will be posted on the Company’s website following the presentation. Event:   J.P. M

SAN MATEO, Calif.–(BUSINESS WIRE)–Mendaera Inc., a healthcare technology company creating a first-of-its-kind handheld robotic platform to revolutionize the delivery of prevalent interventional procedures, today announced the appointment of Eric Davidson as its first Chief Commercial Officer (CCO). Davidson will lead commercialization efforts as the company prepares for market entry with its novel robotic technologies. Davidson joins Mendaera with more than two decades of leadership in medica

ESSEX, Conn.–(BUSINESS WIRE)– #BLT1–Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, small molecule drug candidate targeting the BLT1 receptor to treat inflammatory bowel disease (IBD), Crohn’s disease and ulcerative colitis, today announced that the company has secured an additional $8.975 million in program-related investment funding in the form of a loan from The Leona M. and Harry B. Helmsley Charitable Trust (“Helmsley”), bringing Helmsley’s t

BASEL, Switzerland–(BUSINESS WIRE)–Demonstrated Robust Dose-Dependent Target Engagement, Preliminary Evidence of Improved Organ Function and a Favorable Safety Profile